Cullinan Therapeutics

Cullinan Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer. Its pipeline includes T-cell engager programs and small-molecule oncology assets such as zipalertinib, with development-stage candidates spanning immunology and oncology.

Relationship details are part of the Pro plan.